Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels.
Endogenex has raised $88.0M in total funding. The most recent round was Series C. The last funding was announced in June 2024.
Endogenex's investors include Longitude Capital, Hatteras Venture Partners, Lumira Ventures, Mayo Clinic, Intuitive Ventures.
Endogenex is headquartered in Plymouth, United States.
Endogenex develops an endoscopic procedure to help patients with type 2 diabetes regain control of their blood glucose levels.
Endogenex is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endogenex — Funding & Investors." VCBacked, June 25, 2024, https://www.vcbacked.co/company/endogenex. Accessed September 14, 2026.
VCBacked. (2024). Endogenex — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/endogenex
{{cite web |title=Endogenex — Funding & Investors |url=https://www.vcbacked.co/company/endogenex |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated